Biotronik said yesterday that its Orsiro stent tops the Xience stents made by Abbott (NYSE:ABT) when it comes to target lesion failure, according to data from a clinical trial. The randomized, controlled BioSTEMI trial was the first direct comparison between the two drug-eluting stents in patients with acute ST-segment elevation myocardial infarction (STEMI). Biotronik announced […]
European Society of Cardiology (ESC)
ESC Congress 2015: St. Jude, HeartFlow tout FFR-guided PCI
The European Society of Cardiology Congress conference wrapped up this week in London. Here’s a roundup of news from the overseas meeting of interventional cardiologists, dominated by data on fractional flow reserve technology. FFR: St. Jude touts 5 year data showing long-term benefits St. Jude Medical (NYSE:STJ) released 5-year data from a trial comparing the use […]
St. Jude Medical’s Nanostim leadless pacer meets 6-month safety, efficacy goals
The Nanostim implantable pacemaker made by St. Jude Medical (NYSE:STJ) met its 6-month safety and efficacy endpoints, according to data presented over the weekend at the annual meeting of the European Society of Cardiology in London and published in the New England Journal of Medicine. The Leadless II study enrolled 526 patients in the primary cohort, with 300 […]
Medtronic says a pair of studies show genetic link to sudden cardiac death
Medtronic (NYSE:MDT) today said 1st-of-a-kind results from a pair of independent clinical trials discovered a gene linked to abnormal heart rhythms that can lead to sudden cardiac death. Fridley, Minn.-based Medtronic said the studies, Discovery and Oregon SUDS, found a gene associated with SCD in patients with implantable cardioverter defibrillators. Results were presented over the weekend […]